A Study of Baricitinib for Delaying Type 1 Diabetes
Phase 3
150
about 5.5 years
1–35
7 sites in FL, IA, KY +2
About this study
Researchers are testing if baricitinib can delay the onset of type 1 diabetes in people at high risk. The trial will last up to five years and involve approximately 150 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Baricitinib
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
baricitinib
oral (Oral Tablet)
Secondary: Change from Baseline in AUC Ratio (AUC C-peptide/AUC Glucose × 1000), Change from Baseline in Body Mass Index (BMI) Percentile, Change from Baseline in Glucose AUC, Change from Baseline in Glucose-Stimulated C-peptide Area Under the Curve (AUC), Change from Baseline in Height, Change from Baseline in Matsuda Index, Change from Baseline in Short Form 36 Version 2 Health Survey, Acute (SF-36v2), PK: Area Under the Concentration Versus Time Curve (AUC) of Baricitinib
Endocrinology